Cargando…
Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786606/ https://www.ncbi.nlm.nih.gov/pubmed/35093212 http://dx.doi.org/10.1016/j.ccell.2022.01.010 |
| _version_ | 1784639147842994176 |
|---|---|
| author | Sesques, Pierre Bachy, Emmanuel Ferrant, Emmanuelle Safar, Violaine Gossez, Morgane Morfin-Sherpa, Florence Venet, Fabienne Ader, Florence |
| author_facet | Sesques, Pierre Bachy, Emmanuel Ferrant, Emmanuelle Safar, Violaine Gossez, Morgane Morfin-Sherpa, Florence Venet, Fabienne Ader, Florence |
| author_sort | Sesques, Pierre |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8786606 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87866062022-01-25 Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients Sesques, Pierre Bachy, Emmanuel Ferrant, Emmanuelle Safar, Violaine Gossez, Morgane Morfin-Sherpa, Florence Venet, Fabienne Ader, Florence Cancer Cell Letter Elsevier Inc. 2022-03-14 2022-01-25 /pmc/articles/PMC8786606/ /pubmed/35093212 http://dx.doi.org/10.1016/j.ccell.2022.01.010 Text en © 2022 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter Sesques, Pierre Bachy, Emmanuel Ferrant, Emmanuelle Safar, Violaine Gossez, Morgane Morfin-Sherpa, Florence Venet, Fabienne Ader, Florence Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients |
| title | Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients |
| title_full | Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients |
| title_fullStr | Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients |
| title_full_unstemmed | Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients |
| title_short | Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients |
| title_sort | immune response to three doses of mrna sars-cov-2 vaccines in cd19-targeted chimeric antigen receptor t cell immunotherapy recipients |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786606/ https://www.ncbi.nlm.nih.gov/pubmed/35093212 http://dx.doi.org/10.1016/j.ccell.2022.01.010 |
| work_keys_str_mv | AT sesquespierre immuneresponsetothreedosesofmrnasarscov2vaccinesincd19targetedchimericantigenreceptortcellimmunotherapyrecipients AT bachyemmanuel immuneresponsetothreedosesofmrnasarscov2vaccinesincd19targetedchimericantigenreceptortcellimmunotherapyrecipients AT ferrantemmanuelle immuneresponsetothreedosesofmrnasarscov2vaccinesincd19targetedchimericantigenreceptortcellimmunotherapyrecipients AT safarviolaine immuneresponsetothreedosesofmrnasarscov2vaccinesincd19targetedchimericantigenreceptortcellimmunotherapyrecipients AT gossezmorgane immuneresponsetothreedosesofmrnasarscov2vaccinesincd19targetedchimericantigenreceptortcellimmunotherapyrecipients AT morfinsherpaflorence immuneresponsetothreedosesofmrnasarscov2vaccinesincd19targetedchimericantigenreceptortcellimmunotherapyrecipients AT venetfabienne immuneresponsetothreedosesofmrnasarscov2vaccinesincd19targetedchimericantigenreceptortcellimmunotherapyrecipients AT aderflorence immuneresponsetothreedosesofmrnasarscov2vaccinesincd19targetedchimericantigenreceptortcellimmunotherapyrecipients |